As part of the collaboration, the US-based company will use its Library of Libraries for the discovery of new antibodies against Artisan Bio’s immunotherapy targets. Meanwhile, Artisan will
The acquisition will help accelerate the company’s growth and establish a footprint in the menopause market. Previously, Amyris announced plans to establish a new consumer brand to offer
APS03118 is a second generation selective rearranged during transfection (RET) inhibitor that targets patients suffering with non-small cell lung cancer, breast cancer, ovarian cancer, thyroid cancer, colorectal cancer,
Senhwa Biosciences acting CEO Mei-Hui Kuo said: “We are pleased to receive ODD for Silmitasertib for the treatment of Biliary Tract Cancer, a rare, malignant disease for which
The date for the FDA decision is on 19 September 2022. The sBLA is backed by results from a randomized, multicenter Phase 3 study. The study investigated Libtayo
Jyseleca is indicated for usage in moderately to severely active UC adult patients, with insufficient, lost response to or were not tolerant to either standard treatment or a
Leveraging Neurimmune’s reverse translational medicine (RTM) technology platform, the alliance will create antibody therapies against new treatment targets in the neurodegenerative disease field. RTM technology platform is a
The latest move follows the receipt of European Commission (EC) approval for the drug in December last year. Cibinqo, the oral small molecule drug, selectively hinders Janus kinase
As part of the collaboration, the companies will use Prellis Biologics’ externalised human immune system (EXIS) which is based on human lymph node organoids (LNO). The human antibody
The latest move follows the identification of various gene signatures that predict a tumour’s possible response to these drug candidates of Lantern. LP-184 is being analysed as a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.